In this issue:
Anti-FXa levels after once-daily enoxaparin in patients undergoing colorectal surgery
Voxelotor for sickle-cell disease
Induction idarubicin, etoposide + sequential or concurrent azacitidine, + maintenance azacitidine, for AML
Symptom burden and blood counts in polycythaemia vera
Invasive fungal disease after frontline intensive chemotherapy in AML
Guadecitabine for higher-risk myelodysplastic syndrome/low blast count AML after azacitidine failure
FMT for multidrug-resistant bacteria before or after allogeneic SCT in haematological malignancies
Brentuximab + AVD for nonbulky limited-stage classical Hodgkin’s lymphoma
CD19 CAR T-cells after autologous SCT in poor-risk, relapsed/refractory B-cell non-Hodgkin’s lymphoma
Long-term outcomes of MGRS
Please login below to download this issue (PDF)